Michael Kommor, MD
Hematology & Oncology · Louisville, KYNPI 1760453518
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Novartis at 28.4% of the total. That places this record below the midpoint for hematology & oncology clinicians in KY, where the typical reported total is $4,619.
Across 99 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$540
- Bristol Myers Squibb$267
- AstraZeneca$162
- Merck$116
- Pfizer$105
- Gilead$73
- plus $635 from 25 others
Across 3 payments — averaging $8501.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$25K
- E.r. Squibb & Sons, L.L.C.$900
What the payments were for
- Food & beverage$1,77694%
- Education$975%
- Gifts$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $540 |
| Bristol Myers Squibb | 11 | $267 |
| AstraZeneca | 8 | $162 |
| Merck | 7 | $116 |
| Pfizer | 7 | $105 |
| Gilead(2 entities) | 4 | $73 |
| AbbVie | 2 | $68 |
| Astellas Pharma US Inc | 3 | $64 |
| Genentech USA, Inc. | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Fennec Pharmaceuticals, Inc. | 2 | $35 |
| CTI Biopharma Corp. | 2 | $32 |
| GSK | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $31 |
| Tosoh Bioscience, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Foundation Medicine, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| Beigene USA, Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Genmab U.S., Inc. | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Adaptive Biotechnologies Corporation | 1 | $13 |
| Global Blood Therapeutics, Inc. | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
How this compares
$1,898 in reported general payments places this provider in the 30th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 60 | $1,064,634 |
| JakafiRuxolitinib Phosphate | 41 | $731,770 |
| CalquenceAcalabrutinib Maleate | 41 | $601,769 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $368,152 |
| VenclextaVenetoclax | 14 | $202,197 |
| AlecensaAlectinib Hcl | 11 | $198,921 |
| TagrissoOsimertinib Mesylate | 12 | $188,220 |
| CabometyxCabozantinib S-Malate | 11 | $176,157 |
| Lenalidomide | 13 | $168,713 |
| XareltoRivaroxaban | 124 | $111,730 |
| EliquisApixaban | 115 | $103,749 |
| Imatinib Mesylate | 29 | $25,498 |
| VemlidyTenofovir Alafenamide | 12 | $18,448 |
| CreonLipase/Protease/Amylase | 11 | $10,263 |
| PremarinEstrogens, Conjugated | 11 | $4,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $162 | $789,99053 claims |
| GSKOjjaara | $32 | $368,15212 claims |
| AbbVieVenclexta, Creon | $68 | $212,46025 claims |
| Genentech USA, Inc.Alecensa | $40 | $198,92111 claims |
| PfizerEliquis, Premarin | $105 | $108,447126 claims |
| GileadVemlidy | $73 | $18,44812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Louisville
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Jeffrey HargisLouisville$450K
- Mohamed HegaziLouisville$380K
- Khuda KhanLouisville$359K
- Jaspreet GrewalLouisville$280K
- Laila AgrawalLouisville$95K
- Brian DongLouisville$31K
- Rohit KumarLouisville$31K
- Vikas SinghLouisville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.